株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尿管癌:パイプライン製品の分析

Ureter Cancer - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 247802
出版日 ページ情報 英文 206 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
尿管癌:パイプライン製品の分析 Ureter Cancer - Pipeline Review, H2 2018
出版日: 2018年10月16日 ページ情報: 英文 206 Pages
概要

尿管癌の症候は、尿道からの出血あるいは血尿、膿、鼠径部のリンパ節腫大などが見られます。危険因子として喫煙があります。治療は手術、化学療法、放射線療法を行います。

当レポートでは、尿管癌の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

尿管癌 概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Altor BioScience Corp
  • エーザイ
  • Exelixis Inc
  • GlaxoSmithKline Plc
  • MedImmune LLC
  • Merck & Co Inc

薬剤プロファイル

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Ureter Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Ureter Cancer - Pipeline by Altor BioScience Corp, H2 2018
  • Ureter Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Ureter Cancer - Pipeline by BioClin Therapeutics Inc, H2 2018
  • Ureter Cancer - Pipeline by Eisai Co Ltd, H2 2018
  • Ureter Cancer - Pipeline by Exelixis Inc, H2 2018
  • Ureter Cancer - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Ureter Cancer - Pipeline by MacroGenics Inc, H2 2018
  • Ureter Cancer - Pipeline by MedImmune LLC, H2 2018
  • Ureter Cancer - Pipeline by Merck & Co Inc, H2 2018
  • Ureter Cancer - Pipeline by Merck KGaA, H2 2018
  • Ureter Cancer - Pipeline by Pfizer Inc, H2 2018

List of Figures

  • Number of Products under Development for Ureter Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC10894IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H2 2018, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ureter Cancer - Overview
  • Ureter Cancer - Therapeutics Development
  • Ureter Cancer - Therapeutics Assessment
  • Ureter Cancer - Companies Involved in Therapeutics Development
  • Ureter Cancer - Drug Profiles
  • Ureter Cancer - Product Development Milestones
  • Appendix
Back to Top